靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用

doi:10.3760/cma.j.cn371439-20230428-00120

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (10): 631-635.doi: 10.3760/cma.j.cn371439-20230428-00120

靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用

于晓鹏¹, 冯青青², 赵文飞², 赵文文², 魏红梅²()

¹潍坊医学院临床医学院，潍坊 261053
²青岛大学附属青岛市中心医院肿瘤综合二科，青岛 266042

收稿日期:2023-04-28 修回日期:2023-08-01 出版日期:2023-10-08 发布日期:2023-11-08
通讯作者: 魏红梅 E-mail:13001776675@163.com
基金资助:
青岛市医药卫生科研计划(2021-WJZD081)

Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer

Yu Xiaopeng¹, Feng Qingqing², Zhao Wenfei², Zhao Wenwen², Wei Hongmei²()

¹School of Clinical Medicine， Weifang Medical University， Weifang 261053， China
²Second Department of General Oncology， Affiliated Qingdao Central Hospital， Qingdao University， Qingdao 266042， China

Received:2023-04-28 Revised:2023-08-01 Online:2023-10-08 Published:2023-11-08
Contact: Wei Hongmei E-mail:13001776675@163.com
Supported by:
Qingdao Medical and Health Research Project(2021-WJZD081)

摘要/Abstract

摘要：

人表皮生长因子受体2（HER2）、程序性死亡受体1、程序性死亡受体配体1与多种肿瘤细胞的增殖、侵袭和转移相关，靶向HER2的多种抗体及小分子药物已在临床取得可观的结果，针对程序性死亡受体1、程序性死亡受体配体1的免疫检查点抑制剂在临床应用中效果显著。在KEYNOTE-811试验中，免疫检查点抑制剂与靶向治疗的联合应用在HER2阳性进展期胃癌中取得了令人振奋的结果。

关键词: 胃肿瘤, 受体，erbB-2, 免疫检查点抑制剂

Abstract:

Human epidermal growth factor receptor 2 （HER2）， programmed death-1 and programmed death-ligand 1 are related to the proliferation， invasion and metastasis of various tumor cells. A variety of antibodies and small molecule drugs targeting HER2 have achieved considerable results in clinical practice. Immune checkpoint inhibitors targeting programmed death-1 and programmed death-ligand 1 have significant effects in clinical application. In the KEYNOTE-811 trial， the combination of immune checkpoint inhibitors and targeted therapy has achieved encouraging results in HER2-positive advanced gastric cancer.

Key words: Stomach neoplasms, Receptor， erbB-2, Immune checkpoint inhibitors

于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.

Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.

参考文献 29

[1]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022.
[2]	Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J]. Cancer Lett, 2018, 430: 47-56. DOI: 10.1016/j.canlet.2018.05.009. pmid: 29746929
[3]	Voutsadakis IA. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer[J]. Clin Transl Oncol, 2019, 21(5): 539-555. DOI: 10.1007/s12094-018-1961-x. pmid: 30306401
[4]	Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J]. Br J Cancer, 2021, 124(3): 595-603. DOI: 10.1038/s41416-020-01138-3.
[5]	Iwata TN, Ishii C, Ishida S, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model[J]. Mol Cancer Ther, 2018, 17(7): 1494-1503. DOI: 10.1158/1535-7163.MCT-17-0749. pmid: 29703841
[6]	Mandikian D, Takahashi N, Lo AA, et al. Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model[J]. Mol Cancer Ther, 2018, 17(4): 776-785. DOI: 10.1158/1535-7163.MCT-17-0657. pmid: 29339550
[7]	Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600(7890): 727-730. DOI: 10.1038/s41586-021-04161-3.
[8]	Subramanian J, Katta A, Masood A, et al. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers[J]. Oncologist, 2019, 24(12): e1303-e1314. DOI: 10.1634/theoncologist.2018-0845.
[9]	Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway[J]. Sci Adv, 2020, 6(38): eabd2712. DOI: 10.1126/sciadv.abd2712.
[10]	Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of western patients[J]. Oncotarget, 2016, 7(17): 24269-24283. DOI: 10.18632/oncotarget.8169. pmid: 27009855
[11]	赵丽丽, 赵文文, 冯青青, 等. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710. DOI: 10.3760/cma.j.cn371439-20210813-00140.
[12]	Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status[J]. Cancer Med, 2018, 7(6): 2612-2620. DOI: 10.1002/cam4.1502.
[13]	Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance[J]. Dig Liver Dis, 2022, 54(10): 1419-1427. DOI: 10.1016/j.dld.2022.01.128.
[14]	Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013.DOI: 10.1001/jamaoncol.2018.0013.
[15]	Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133. DOI: 10.1016/S0140-6736(18)31257-1. pmid: 29880231
[16]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
[17]	Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol, 2019, 20(3): 371-382. DOI: 10.1016/S1470-2045(18)30812-X. pmid: 30765258
[18]	Rha SY, Lee CK, Kim HS, et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ⅰb/Ⅱ trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC)[J]. J Clin Oncol, 2020, 38(38(15_suppl): 3081. DOI: 10.1200/JCO.2020.
[19]	Lee CK, Rha SY, Kim HS, et al. A single arm phase Ⅰb/Ⅱ trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer[J]. Nat Commun, 2022, 13(1): 6002. DOI: 10.1038/s41467-022-33267-z.
[20]	Wang KX, Cui TY, Yang XD, et al. Study on efficacy and safety of low-dose apatinib combined with camrelizumab and SOX regimen as first-line treatment of locally advanced and unresectable gastric/gastroesophageal junction cancer: a protocol for an open-label, dose escalation and extension phaseⅠb clinical trial[J]. Onco Targets Ther, 2021, 14: 4859-4865. DOI: 10.2147/OTT.S316288.
[21]	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (version 1.2023)[EB/OL]. [2023-04-10]. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
[22]	Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019, 125(5): 742-749. DOI: 10.1002/cncr.31855. pmid: 30508306
[23]	Xu M, Meng X, Lu Y, et al. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer[J]. J Gastrointest Oncol, 2022, 13(2): 548-558. DOI: 10.21037/jgo-21-897. pmid: 35557572
[24]	张鑫鑫, 李帅, 吴晨, 等. HER-2阳性晚期胃癌免疫治疗临床分析[J]. 中国肿瘤临床, 2022, 49(16): 840-845. DOI: 10.12354/j.issn.1000-8179.2022.20220156.
[25]	Markham A. Margetuximab: first approval[J]. Drugs, 2021, 81(5): 599-604. DOI: 10.1007/s40265-021-01485-2. pmid: 33761116
[26]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076. DOI: 10.1016/S1470-2045(20)30326-0.
[27]	Stein A, Paschold L, Tintelnot J, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial[J]. JAMA Oncol, 2022, 8(8): 1150-1158. DOI: 10.1001/jamaoncol.2022.2228. pmid: 35737383
[28]	Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2⁺ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma[J]. Future Oncol, 2021, 17(10): 1155-1164. DOI: 10.2217/fon-2020-1007. pmid: 33263418
[29]	Catenacci DVT, Kang YK, Yoon HH, et al. Margetuximab with retifanlimab as first-line therapy in HER2⁺/PD-L1⁺ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A[J]. ESMO Open, 2022, 7(5): 100563. DOI: 10.1016/j.esmoop.2022.100563.

靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用

Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[4]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[5]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[6]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[7]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	陈欣祎, 翁一鸣, 魏家燕, 王劲松, 彭敏. 免疫检查点抑制剂在复发或转移性头颈部鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 553-557.
[10]	邓隽军, 赵大勇, 李淼. 免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[11]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[12]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[13]	过慈良, 江春平, 吴俊华. 肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[14]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[15]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.